FindTrial
Sign In

Efficacy and safety of neoadjuvant immunotherapy versus neoadjuvant chemotherapy in patients with non-small cell lung cancer: a single-center, retrospective, non-intervention study

Efficacy and safety of neoadjuvant immunotherapy versus neoadjuvant chemotherapy in patients with non-small cell lung cancer: a single-center, retrospective, non-intervention study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076644
Enrollment
Unknown
Registered
2023-10-13
Start date
2023-10-13
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Neoadjuvant chemotherapy subgroup:None
Neoadjuvant immunotherapy subgroup:None

Sponsors

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Over the age of 18; (2) Patients with non-small cell lung cancer confirmed by histological and/or cytological examination; (3) Comprehensive clinical and pathological information can be obtained; (4) Receive neoadjuvant therapy, and relevant information is comprehensive.

Exclusion criteria

Exclusion criteria: (1) Diagnosed with tumors other than lung cancer before receiving neoadjuvant therapy or have a history of tumors; (2) Any other clinically significant disease or condition that the investigator deems inappropriate for inclusion in this study.

Design outcomes

Primary

MeasureTime frame
survival time;Operation time;—

Secondary

MeasureTime frame
Duration of hospitalization;Demographic data;Intraoperative blood loss;Time for chest tube;—

Countries

China

Contacts

Public ContactShugeng Gao

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

gaoshugeng@cicams.ac.cn+86 67781331

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026